Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertapenem Duration in Acute Sigmoid Diverticulitis
NCT00097734Phase 4Unknown
- Sponsor
- KRH Klinikum Siloah
- Start
- Jul 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ertapenem in sigmoid diverticulitis (2 arms), sponsored by KRH Klinikum Siloah. Primary endpoints: Clinical therapeutic success (full regression) at 1 month, Relapse rate at 1 year and 1 more. Status: unknown.
02
Drugs
ertapenem
03
Conditions
sigmoid diverticulitis
Beyond the preview
Go deeper on NCT00097734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00097734.